Reduction of PaCO2 by high-flow nasal cannula in acute hypercapnic respiratory failure patients receiving conventional oxygen therapy

Hyun Woo Lee; Sun Mi Choi; Jinwoo Lee; Young Sik Park; Chang-Hoon Lee; Chul-Gyu Yoo; Young Whan Kim; Sung Koo Han; Sang-Min Lee

doi:10.4266/acc.2019.00563

Articles

Page Path: HOME > Acute Crit Care > Volume 34(3); 2019 > Article

Original Article Pulmonary Reduction of PaCO₂ by high-flow nasal cannula in acute hypercapnic respiratory failure patients receiving conventional oxygen therapy: Acute and Critical Care 2019;34(3):202-211.
DOI: https://doi.org/10.4266/acc.2019.00563
Published online: August 31, 2019

Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea

Corresponding author Sang-Min Lee Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul 03080, Korea Tel: +82-2-2072-0833 Fax: +82-2-764-2199 E-mail: sangmin2@snu.ac.kr

• Received: May 21, 2019 • Revised: August 5, 2019 • Accepted: August 9, 2019

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

20,886 Views
254 Download
19 Web of Science
18 Crossref
17 Scopus

prev next

Full Article

Download PDF

Abstract
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
KEY MESSAGES
NOTES
REFERENCES

Abstract

Background:
It has been suggested that a high-flow nasal cannula (HFNC) could help to remove carbon dioxide (CO₂) from anatomical dead spaces, but evidence to support that is lacking. The objective of this study was to elucidate whether use of an HFNC could reduce the arterial partial pressure of CO₂ (PaCO₂) in patients with acute hypercapnic respiratory failure who are receiving conventional oxygen (O₂) therapy.
Methods:
A propensity score-matched observational study was conducted to evaluate patients treated with an HFNC for acute hypercapnic respiratory failure from 2015 to 2016. The hypercapnia group was defined as patients with a PaCO₂ >50 mm Hg and arterial pH <7.35.
Results:
Eighteen patients in the hypercapnia group and 177 patients in the nonhypercapnia group were eligible for the present study. Eighteen patients in each group were matched by propensity score. Decreased PaCO₂ and consequent pH normalization over time occurred in the hypercapnia group (P=0.002 and P=0.005, respectively). The initial PaCO₂ level correlated linearly with PaCO₂ removal after the use of an HFNC (R²=0.378, P=0.010). The fraction of inspired O₂ used in the intensive care unit was consistently higher for 48 hours in the nonhypercapnia group. Physiological parameters such as respiratory rate and arterial partial pressure of O₂ improved over time in both groups.
Conclusions:
Physiological parameters can improve after the use of an HFNC in patients with acute hypercapnic respiratory failure given low-flow O₂ therapy via a facial mask. Further studies are needed to identify which hypercapnic patients might benefit from an HFNC.
Key Words: hypercapnia; oxygen inhalation therapy; respiratory insufficiency

INTRODUCTION

The high-flow nasal cannula (HFNC) has several physiological benefits, one of which is to facilitate carbon dioxide (CO₂) washout from the airway system [1-3]. Although the theoretical background for CO₂ “sweeping” has been explained in various ways, previous studies have consistently reported improved ventilation after the use of an HFNC [4]. For example, breathing frequency and minute ventilation decrease without changing the arterial partial pressure of CO₂ (PaCO₂), which makes respiratory ventilation more efficient by decreasing the dead space [5,6]. Some researchers have suggested that reducing the overall dead space in the airway system can improve respiratory ventilation and ultimately help to remove CO₂ [7,8]. Others have reported that the endexpiratory lung volume increases after the application of an HFNC, which might result in collapsed alveoli and increase gas flow [9,10]. However, the guidelines for managing acute hypercapnic respiratory failure recommend noninvasive ventilation (NIV) as the treatment of choice and suggest that an HFNC should not be used because of a lack of evidence for the benefits and the possibility of respiratory suppression [11,12]. Although intolerance or lung injury caused by the application of bilevel pressure has frequently been reported in patients treated with noninvasive or invasive ventilation, no alternative noninvasive options have been suggested [13,14].

Recent clinical trials have reported the benefits of using an HFNC to treat patients with obstructive lung disease or hypercapnia. The short-term application of an HFNC decreases the transcutaneous CO₂ level and improves other physiological parameters in patients who require long-term oxygen (O₂) therapy to treat stable chronic obstructive pulmonary disease (COPD) [15]. For example, the PaCO₂ level decreased more as the rate of gas flow in an HFNC increased in stable COPD patients [16]. In another study, HFNCs allowed patients with severe COPD to increase their exercise capacity without retaining CO₂ [17]. Short-term use of an HFNC causes a decrease in transcutaneous CO₂ levels even during an acute exacerbation of COPD [18]. Most of the previous studies on the use of an HFNC in treating hypercapnia have focused exclusively on relatively stable patients without considering patients with unstable hypercapnic status.

We conducted the present study to clarify whether, compared with nonhypercapnic patients, hypercapnic patients exhibit a tendency for CO₂ retention or CO₂ removal after the use of an HFNC. Our aim in the present study was to elucidate how physiological parameters change in relation to the initial PaCO₂ level after the use of an HFNC in patients with acute respiratory failure given a facial mask for O₂ therapy.

MATERIALS AND METHODS

Study Population and Study Design

This propensity score-matched cohort study was conducted by reviewing the electronic medical records in a tertiary teaching hospital. The study population comprised patients admitted to our hospital and given O₂ therapy via an HFNC to manage acute respiratory failure between January 2015 and December 2016. The inclusion criteria were as follows: (1) the patient could breathe spontaneously without impaired mental status, (2) the patient was given O₂ therapy with a facial mask before the application of an HFNC, (3) an HFNC was applied for at least 48 hours, (4) physiological parameters were measured continuously during HFNC use, and (5) the patient’s age >18 years. The exclusion criteria were any of the following conditions that could influence the targeted physiological parameters other than acute respiratory failure: (1) concurrent metabolic acidosis or alkalosis, (2) hemodialysis or peritoneal dialysis, (3) extracorporeal membrane oxygenation or extracorporeal CO₂ removal, or (4) invasive or noninvasive mechanical ventilation.

The study population was classified into hypercapnia and nonhypercapnia groups. The hypercapnia group was defined as patients with acute hypercapnic respiratory failure, PaCO₂ >50 mm Hg, and arterial pH <7.35 [11,19]. Both groups were given conventional O₂ therapy with a facial mask for hypoxemia until an HFNC was applied.

We first reviewed the demographic characteristics (age, sex, body mass index, level of consciousness, declaration of a “do not resuscitate” or “do not intubate order,” department to which the patient was admitted, and comorbid chronic conditions). We recorded PaCO₂, arterial pH, arterial partial pressure of O₂ (PaO₂), mean blood pressure, heart rate, respiratory rate, body temperature, O₂ saturation, applied O₂ flow rate, and applied fraction of inspired oxygen (FiO₂). These parameters were checked at baseline and at 12, 24, and 48 hours after HFNC initiation. The variation in PaCO₂ during the first 12 hours of HFNC use was recorded. The causes of acute respiratory failure were analyzed. The severity of each patient’s condition was assessed using the Acute Physiology and Chronic Health Evaluation (APACHE) II score, Sequential Organ Failure Assessment (SOFA) score, and the ratio of PaO₂ to FiO₂. For evaluation of clinical outcomes, we reviewed in-hospital mortality, survived days, and cause of death.

Assessment of Physiological and Clinical Outcomes

The primary aim of this study was to determine the variation in PaCO₂ level before and after HFNC application for 48 hours. The secondary aim was to assess the associations between the change in PaCO₂ during the first 12 hours of HFNC use and the initial level of PaCO₂, respiratory rate, and O₂ flow rate in the hypercapnia group. We also analyzed the changes in other physiological parameters such as pH, PaO₂, mean blood pressure, heart rate, and respiratory rate over time. The in-hospital mortality rate within 28 days, mean survival time within 28 days, and cause of mortality were evaluated.

Statistics

Categorical variables were compared using Pearson’s chisquare test or Fisher’s exact test. Continuous variables were analyzed using the Student t-test, and the results are described using the mean and standard deviation. We created propensity scores using logistic regression analyses with demographic characteristics, underlying disease, results of blood tests except for arterial blood gas analysis (ABGA), cause of respiratory failure, initial vital signs, use of inotropes, and severity indexes as covariates. Propensity score matching was conducted at a one-to-one ratio. Repeated-measures analysis of variance in the propensity score–matched population was performed to identify significant changes in physiological parameters over time and differences between the hypercapnia and nonhypercapnia groups. Regression analysis with scatterplots was used to explain the relationships between CO₂ washout and other factors. We used R ver. 3.4.0 (R Core Team 2017, Vienna, Austria) for our statistical analyses.

Ethics

The Institutional Review Board of Seoul National University Hospital examined and approved the protocol for our study and exempted us from the need for informed consent to access to the electronic medical records (IRB No. H-1704-085-665).

RESULTS

Baseline Characteristics of the Study Population

In total, 195 patients were eligible and subsequently classified into two groups: 18 patients in the hypercapnia group and 177 in the nonhypercapnia group (Figure 1). All patients were supplied with 11–15 L of O₂ via a face mask before the application of an HFNC. In the analysis of the total study population, demographic features and the causes of respiratory failure showed significant heterogeneity between groups (Tables 1 and 2). Male sex and underlying cardiovascular disease were found more frequently in the hypercapnia group, and immune deficiency occurred in more patients in the nonhypercapnia group. The frequency of underlying chronic respiratory disease and acute exacerbation of COPD did not differ significantly between the two groups. A higher FiO₂ was applied to the nonhypercapnia group, but the O₂ flow rate was similar between groups. The initial vital signs, use of inotropes, and disease severity did not differ significantly between groups.

Eighteen patients in each group were matched one-to-one using the propensity score. The heterogeneity of the baseline characteristics and clinical features was adjusted and minimized, except for the targeted physiological parameters (Tables 3 and 4). The mean age was >70 years, and about 90% of the patients were men. More than half of the patients had a declared “do not resuscitate order,” and about one-third of the patients had a declared “do not intubate order.” Pneumonia, pulmonary edema, and acute exacerbation of COPD were the main causes of respiratory failure. The initial mean respiratory rate was about 30 per minute, and the mean oxygen saturation was about 90%. The mean APACHE II score was about 18, and mean SOFA score was about 6. In the ABGA, the hypercapnia group had a lower pH (7.31±0.09) and higher PaCO₂ (61.5±15.1 mm Hg). A higher FiO₂ was used with the HFNC in the nonhypercapnia group.

Physiological Parameters in the Propensity Score–Matched Patients

The PaCO₂ level changed over time, but the pattern of change differed between patient groups (P=0.002 for the interaction of group and time) (Figure 2A). The PaCO₂ level decreased over time (–11.2±12.7 mm Hg for 48 hours) in the hypercapnia group but tended to increase over time (5.2±12.2 mm Hg for 48 hours) in the nonhypercapnia group (P<0.001 for the interaction of group and time).

In the hypercapnia group, the variation in PaCO₂ during the first 12 hours was related to the initial PaCO₂ level; that is, more CO₂ was washed out by the HFNC in patients with a higher PaCO₂ (R²=0.378, P=0.010) (Figure 3). The decrease in PaCO₂ was not related to the respiratory rate or O₂ flow rate.

For pH, the pattern of change over time also differed between the groups (P=0.005 for the interaction of group and time) (Figure 2B). The pH increased with time in the hypercapnia group but remained constant in the nonhypercapnia group. PaO₂ increased over time in both groups (P=0.001) (Figure 2C). All patients were supplied with 11–15 L of O₂ via a facial mask before the application of an HFNC. The respiratory rate decreased similarly over time in both groups (P<0.001) (Figure 4A). The heart rate had decreased at 12 hours and then increased slightly at 24 and 48 hours, but the changes with time and differences between groups were not significant (Figure 4B). FiO₂ did not change over time but did differ significantly between the groups: FiO₂ was higher in the nonhypercapnia group (Figure 5A). The O₂ flow rate increased for 24 hours and then decreased in the hypercapnia group, but it decreased slightly for 12 hours and then increased in the nonhypercapnia group (Figure 5B).

Ten patients (55.6%) in the hypercapnia group and 11 patients (61.1%) in the nonhypercapnia group died in the hospital (P=0.735) (Table 5). During the 28 days after the initiation of HFNC, the mean survival time was 16.9 days in the hypercapnia group and 17.2 days in the nonhypercapnia group (P=0.522). In the hypercapnia group, hypercapnia was aggravated in six patients, and intubation was performed in one patient 48 hours after the application of HFNC. The causes of death in the hypercapnia group were respiratory failure in eight patients, septic shock in one patient, and cardiac arrest in one patient. The eight patients in the hypercapnia group who died because of respiratory failure had an insufficient reduction in CO₂ (–2.6±8.5 mm Hg for 48 hours) compared with the other 10 patients (–18.1±11.5 mm Hg for 48 hours, P<0.001).

DISCUSSION

We found a significant decrease in PaCO₂ over time after use of an HFNC in patients with acute hypercapnic respiratory failure given O₂ therapy via a face mask. The amount of CO₂ washout in the hypercapnia group was significantly related to the initial PaCO₂ level but not to the respiratory rate or O₂ flow rate. Physiological parameters such as pH, PaO₂, and respiratory rate improved over time after the use of an HFNC in both groups. The applied O₂ flow rate did not differ significantly between the groups during the 48 hours of HFNC use. FiO₂ was consistently set higher in the nonhypercapnia group. Inhospital mortality and mean survival time did not differ significantly between the hypercapnia and nonhypercapnia groups.

Our results show that use of an HFNC in the hypercapnia group did not necessarily exacerbate CO₂ retention, but instead seemed to be beneficial for CO₂ removal, which was not observed in the nonhypercapnia group. This could indicate that the HFNC reduced the PaCO₂ level by increasing the clearance of CO₂ from anatomical dead spaces. Increased dead space is a well-known mechanism underlying hypercapnia and insufficient ventilation [20]. Rapid shallow breathing, which is commonly observed in acute respiratory failure, can increase the dead space, and increased dead space can contribute to hypercapnia [21]. Therefore, the patients in the hypercapnic group were more likely than those in the nonhypercapnic group to have had large dead-space ventilation. Our data thus suggest that the reduction in PaCO₂ in the hypercapnic group occurred through the HFNC “sweeping” CO₂ from the dead space.

Recent studies have shown that continuous positive airway pressure (CPAP) is beneficial for inducing CO₂ washout. In COPD and COPD overlap syndrome, CPAP can be useful for gas exchange in hypercapnic patients [22,23]. Our findings are consistent with those of a small prospective clinical study that showed that HFNC was more helpful for CO₂ reduction than a mask [24]. HFNC is primarily intended to provide a constantly high FiO₂, but it also supplies 1.5–3.1 cm H₂O of CPAP and reduces airway resistance [25,26]. The effects of HFNC on airway pressure or resistance could be one reason for the reduction in PaCO₂ in our study.

It is important to know why the patients in the hypercapnia group were not given NIV or invasive ventilation. Seven patients (or their family) refused to start NIV or invasive ventilation, and 11 patients could not tolerate NIV but could tolerate an HFNC. Even though four patients still exhibited CO₂ retention after use of an HFNC, NIV or mechanical ventilation was not applied because they refused that treatment. One patient was intubated after 48 hours. The decision to use an HFNC seemed to be heterogeneous and depended largely on each patient’s preference for or tolerance of the treatment modality.

CO₂ retention is caused by ventilatory impairment, which can result from various diseases [11]. Ventilation support with fractionated O₂ therapy is the principal therapy used to manage acute hypercapnia [25]. O₂ therapy with a high FiO₂ aggravates CO₂ retention in COPD patients [27]. However, an HFNC can supply a stable flow of O₂ with a high FiO₂. An HFNC is beneficial for oxygenation, but not ventilation, compared with conventional O₂ therapy [28]. Despite some controversy, several clinical trials involving an HFNC in hypercapnic patients have been conducted [15-18]. The background rationale for these trials is the physiological principle that efficient ventilation in the form of an HFNC could reduce dead space [7,8]. An HFNC could, therefore, be a promising alternative or intermediate option before the use of NIV because it has better clinical outcomes in some patients with acute respiratory failure [29]. Our study also shows how physiological parameters improved with time after the change from a face mask to an HFNC, which might have decreased the anatomic dead space. Although four patients in the hypercapnia group became worse with the use of an HFNC, there was sufficient time for them to try NIV again if requested. Given that the PaCO₂ changed little with use of an HFNC in patients from the hypercapnia group who died due to respiratory failure, a sufficient reduction in PaCO₂ with HFNC use might be a good prognostic indicator.

This study has several limitations. First, it was conducted retrospectively, and unknown confounding factors could not be controlled. However, we performed propensity score matching to minimize the effects of confounding variables. Second, our study population did not represent general patients with acute respiratory failure. Although pneumonia accounted for more than half of the causes of respiratory failure, our patients also had other causative diseases. A considerable number of patients had a terminal status and chose to use an HFNC to avoid invasive procedures or uncomfortable treatments. Therefore, our study suggests that an HFNC might be tried before intubation in patients who cannot tolerate noninvasive positive ventilation, but it is unclear whether this would be beneficial in a specific causative disease. Third, patients who were intubated or noninvasively ventilated within 48 hours of HFNC use were excluded because their serial physiological parameters could have been affected by the use of supported gas ventilation. Fourth, we did not evaluate patients with a severe condition who needed immediate intubation for severe respiratory acidosis, a low level of consciousness, or intractable lung injury. Further studies are needed to identify which subgroups of patients with acute hypercapnic failure can benefit from the use of an HFNC. Finally, we could not confirm whether improvements in physiological parameters were related to better clinical outcomes. We analyzed a single arm from a cohort database in which the patients started HFNC when acute respiratory failure was diagnosed.

In conclusion, HFNC use decreased PaCO₂ in patients with various causes of acute hypercapnic respiratory failure. The results of the present study apply to the limited study population who used an HFNC for at least 48 hours.

KEY MESSAGES

▪ After switching from conventional oxygen therapy with facial mask to high-flow nasal cannula, decrease in arterial partial pressure of carbon dioxide (PaCO₂), consequent pH normalization, and recovery of respiratory rate were found during 48 hours among patients with acute hypercapnic respiratory failure.

▪ The amount of CO₂ washout in the hypercapnia group was significantly related to the initial PaCO₂ level but not to the respiratory rate or O₂ flow rate.

▪ In propensity score-matched population, in-hospital mortality and mean survival time did not differ significantly between the hypercapnia and nonhypercapnia groups.

NOTES

CONFLICT OF INTEREST No potential conflict of interest relevant to this article was reported.

AUTHOR CONTRIBUTIONS

Conceptualization: HWL, SML. Data curation & Formal analysis: HWL. Methodology: HWL, SMC, JL, YSP, SML. Project administration: HWL, SML. Visualization: HWL. Writing - original draft: HWL. Writing - review & editing: CHL, CGY, YWK, SKH, SML.

Figure 1.

Flowchart showing the classification and propensity score matching of acute respiratory failure patients. HFNC: high-flow nasal cannula.

Figure 2.

Sequential measurements of arterial partial pressure of carbon dioxide (PaCO₂, A), pH (B), and arterial partial pressure of oxygen (PaO₂, C) during the use of a high-flow nasal cannula.

Figure 3.

Association between carbon dioxide (CO₂) washout during the first 12 hours and initial arterial partial pressure of carbon dioxide (PaCO₂) level.

Figure 4.

Sequential measurements of respiratory rate (A) and heart rate (B) during the use of a high-flow nasal cannula.

Figure 5.

Sequential measurements of fraction of inspired oxygen (FiO₂, A) and oxygen (O₂) flow rate (B) during the use of a high-flow nasal cannula.

Table 1.

Baseline characteristics in the total study population

Variable	Hypercapnia group (n=18)	Nonhypercapnia group (n=177)	P-value
Age (yr)	70.5±12.2	66.0±13.1	0.166
Male sex	16 (88.9)	116 (65.6)	0.044
Body mass index (kg/m²)	20.9±2.7	21.4±3.7	0.601
Glasgow coma scale	14.5±1.2	14.9±0.4	0.243
Do not resuscitate	11 (61.1)	95 (53.7)	0.546
Do not intubate	7 (38.9)	59 (33.3)	0.635
Department
Medical intensive care unit	18 (100)	166 (93.8)	0.276
Previous history of ICU admission	6 (33.3)		-
Underlying disease
Cardiovascular disease	8 (44.4)	34 (19.2)	0.013
Cardiomyopathy	6 (33.3)	46 (26.0)	0.502
Diabetes mellitus	5 (27.8)	49 (27.7)	0.993
Chronic respiratory disease	8 (44.4)	46 (26.0)	0.095
Malignancy	9 (50.0)	107 (60.5)	0.389
Immune deficiency	6 (33.3)	109 (61.6)	0.020
Liver cirrhosis	4 (22.2)	17 (9.6)	0.100
Chronic kidney disease	5 (27.8)	27 (15.3)	0.172
Blood test
Total white blood cell count (/μl)	16,000±27,034	11,682±8,323	0.509
Hematocrit (%)	32.5±7.0	31.4±5.8	0.433
Creatinine (mg/dl)	2.2±2.1	1.4±1.3	0.161
PH	7.31±0.09	7.43±0.07	<0.001
PaO₂ (mm Hg)	64.5±21.4	73.0±25.2	0.168
PaCO₂ (mm Hg)	61.5±15.1	34.6±5.9	<0.001

Values are presented as mean±standard deviation or number (%).

ICU: intensive care unit; PaO₂: arterial partial pressure of oxygen; PaCO₂: arterial partial pressure of carbon dioxide.

Table 2.

Assessment of the clinical conditions in the total population

Variable	Hypercapnia group (n=18)	Nonhypercapnia group (n=177)	P-value
Cause of respiratory failure^a
Pneumonia	11 (61.1)	121 (68.4)	0.531
Disease progression^b	3 (16.7)	21 (11.9)	0.555
Pulmonary edema	6 (33.3)	31 (17.5)	0.103
Acute exacerbation of COPD	3 (16.7)	10 (5.6)	0.074
Post-extubation respiratory failure	2 (11.1)	16 (9.0)	0.772
Sepsis	1 (5.6)	13 (7.3)	0.779
Pulmonary embolism	0	6 (3.4)	0.428
Other causes	1 (5.6)	8 (4.5)	0.842
Initial vital sign
Mean blood pressure (mm Hg)	91±15	92±15.0	0.537
Heart rate (/min)	101±23	103±22	0.736
Respiratory rate (/min)	29±7	27±7	0.434
Body temperature (°C)	37.4±0.7	37.4±0.9	0.931
Oxygen saturation (%)	90±6	90±6	0.609
Use of inotropics
Dobutamine	0	3 (1.7)	0.567
Dopamine	0	11 (6.2)	0.276
Norepinephrine	2 (11.1)	14 (7.9)	0.699
Initial setting of high flow oxygen therapy
O₂ flow rate (L/min)	43±10	42±9	0.555
FiO₂	0.58±0.18	0.66±0.16	0.037
APACHE II score	17.8±7.1	17.6±6.3	0.886
SOFA score	6.2±3.1	6.5±3.0	0.662
PF ratio	133±92	118±54	0.508

Values are presented as number (%) or mean±standard deviation.

COPD: chronic obstructive pulmonary disease; O₂: oxygen; FiO₂: fraction of inspired oxygen; APACHE: Acute Physiology and Chronic Health Evaluation; SOFA: Sequential Organ Failure Assessment; PF ratio: PaO₂/FiO₂.

^aOne or more diseases were attributed to acute respiratory failure of each patient;

^bProgression of metastatic malignancy and chronic lung diseases such as interstitial lung disease and tuberculosis-destroyed lung are included.

Table 3.

Baseline characteristics in the propensity score-matched population

Variable	Hypercapnia group (n=18)	Nonhypercapnia group (n=18)	P-value
Age (yr)	70.5±12.2	72.2±9.3	0.648
Male sex	16 (88.9)	17 (94.4)	0.546
Body mass index (kg/m²)	20.9±2.7	20.8±2.5	0.879
Glasgow coma scale	14.5±1.2	14.8±0.4	0.378
Do not resuscitate	11 (61.1)	10 (55.6)	0.735
Do not intubate	7 (38.9)	6 (33.3)	0.729
Department
Medical ICU	18 (100)	18 (100)	-
Previous history of ICU admission	6 (33.3)	6 (33.3)	1.000
Underlying disease
Cardiovascular disease	8 (44.4)	11 (61.1)	0.317
Cardiomyopathy	6 (33.3)	8 (44.4)	0.494
Diabetes mellitus	5 (27.8)	5 (27.8)	1.000
Chronic respiratory disease	8 (44.4)	11 (61.1)	0.317
Malignancy	9 (50.0)	6 (33.3)	0.310
Immune deficiency	6 (33.3)	4 (22.2)	0.457
Liver cirrhosis	4 (22.2)	3 (16.7)	0.674
Chronic kidney disease	5 (27.8)	6 (33.3)	0.717
Blood test
Total white blood cell count (/μl)	16,000±27,034	16,386±11,984	0.956
Hematocrit (%)	32.5±7.0	33.3±5.8	0.721
Creatinine (mg/dl)	2.2±2.1	2.1±1.5	0.878
pH	7.31±0.09	7.42±0.07	<0.001
PaO₂ (mm Hg)	64.5±21.4	69.6±28.1	0.542
PaCO₂ (mm Hg)	61.5±15.1	37.1±6.1	<0.001

Values are presented as mean±standard deviation or number (%).

ICU: intensive care unit; PaO₂: arterial partial pressure of oxygen; PaCO₂: arterial partial pressure of carbon dioxide.

Table 4.

Assessment of clinical conditions in the propensity score–matched population

Variable	Hypercapnia group (n=18)	Nonhypercapnia group (n=18)	P-value
Cause of respiratory failure^a
Pneumonia	11 (61.1)	12 (66.7)	0.729
Disease progression^b	3 (16.7)	2 (11.1)	0.630
Pulmonary edema	6 (33.3)	7 (38.9)	0.729
Acute exacerbation of COPD	3 (16.7)	5 (27.8)	0.423
Post-extubation respiratory failure	2 (11.1)	2 (11.1)	1.000
Sepsis	1 (5.6)	1 (5.6)	1.000
Pulmonary embolism	0	0	-
Other causes	1 (5.6)	2 (11.1)	0.546
Initial vital sign
Mean blood pressure (mm Hg)	91±15	91±13	0.914
Heart rate (/min)	101±23	99±15	0.786
Respiratory rate (/min)	29±7	30±6	0.708
Body temperature (°C)	37.4±0.7	37.1±0.7	0.169
Oxygen saturation (%)	90±6	90±6	0.775
Use of inotropics
Dobutamine	0	1 (5.6)	1.000
Dopamine	0	2 (11.1)	0.486
Norepinephrine	2 (11.1)	1 (5.6)	1.000
Initial setting of high-flow O₂ therapy
O₂ flow rate (L/min)	43±10	45±8	0.648
FiO₂	0.58±0.18	0.69±0.16	0.052
APACHE II score	17.8±7.1	17.7±4.7	0.956
SOFA score	6.2±3.1	5.8±2.3	0.718
PF ratio	133±92	103±39	0.221

Values are presented as number (%) or mean±standard deviation.

^aOne or more diseases were attributed to acute respiratory failure of each patient;

^bProgression of metastatic malignancy and chronic lung diseases such as interstitial lung disease and tuberculosis-destroyed lung are included.

Table 5.

Clinical outcomes in the propensity score-matched population

Variable	Hypercapnia group (n=18)	Nonhypercapnia group (n=18)	P-value
All-cause mortality	10 (55.6)	11 (61.1)	0.735
Cause of death			0.867
Respiratory failure	8 (80.0)	8 (72.7)
Septic shock	1 (10.0)	2 (18.2)
Cardiac arrest	1 (10.0)	1 (9.1)
Others
Survival time during the 28 days after initiation of HFNC (day)	16.9±9.7	17.2±5.4	0.522
Day without HFNC in 7 days	1.9±1.5	2.2±1.8	0.687
Day without HFNC in 14 days	8.8±1.8	8.1±3.7	0.462

Values are presented as number (%) or mean±standard deviation.

HFNC: high-flow nasal cannula.

REFERENCES

1. Hernández G, Roca O, Colinas L. High-flow nasal cannula support therapy: new insights and improving performance. Crit Care 2017;21:62. Article PubMed PMC
2. Curley GF, Laffy JG, Zhang H, Slutsky AS. Noninvasive respiratory support for acute respiratory failure-high flow nasal cannula oxygen or non-invasive ventilation? J Thorac Dis 2015;7:1092-7.PubMed PMC
3. Nishimura M. High-flow nasal cannula oxygen therapy in adults. J Intensive Care 2015;3:15. Article PubMed PMC PDF
4. Dysart K, Miller TL, Wolfson MR, Shaffer TH. Research in high flow therapy: mechanisms of action. Respir Med 2009;103:1400-5.Article PubMed
5. Sztrymf B, Messika J, Mayot T, Lenglet H, Dreyfuss D, Ricard JD. Impact of high-flow nasal cannula oxygen therapy on intensive care unit patients with acute respiratory failure: a prospective observational study. J Crit Care 2012;27:324-e9-13.Article
6. Itagaki T, Okuda N, Tsunano Y, Kohata H, Nakataki E, Onodera M, et al. Effect of high-flow nasal cannula on thoraco-abdominal synchrony in adult critically ill patients. Respir Care 2014;59:70-4.Article PubMed
7. Möller W, Celik G, Feng S, Bartenstein P, Meyer G, Oliver E, et al. Nasal high flow clears anatomical dead space in upper airway models. J Appl Physiol (1985) 2015;118:1525-32.Article PubMed PMC
8. Mündel T, Feng S, Tatkov S, Schneider H. Mechanisms of nasal high flow on ventilation during wakefulness and sleep. J Appl Physiol (1985) 2013;114:1058-65.Article PubMed PMC
9. Corley A, Caruana LR, Barnett AG, Tronstad O, Fraser JF. Oxygen delivery through high-flow nasal cannulae increase endexpiratory lung volume and reduce respiratory rate in postcardiac surgical patients. Br J Anaesth 2011;107:998-1004.Article PubMed PDF
10. Riera J, Pérez P, Cortés J, Roca O, Masclans JR, Rello J. Effect of high-flow nasal cannula and body position on end-expiratory lung volume: a cohort study using electrical impedance tomography. Respir Care 2013;58:589-96.Article PubMed
11. Davidson AC, Banham S, Elliott M, Kennedy D, Gelder C, Glossop A, et al. BTS/ICS guideline for the ventilatory management of acute hypercapnic respiratory failure in adults. Thorax 2016;71 Suppl 2:ii1-35.Article PubMed
12. Diaz O, Iglesia R, Ferrer M, Zavala E, Santos C, Wagner PD, et al. Effects of noninvasive ventilation on pulmonary gas exchange and hemodynamics during acute hypercapnic exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1997;156:1840-5.Article PubMed
13. Schönhofer B, Sortor-Leger S. Equipment needs for noninvasive mechanical ventilation. Eur Respir J 2002;20:1029-36.Article PubMed
14. Mehta S, Hill NS. Noninvasive ventilation. Am J Respir Crit Care Med 2001;163:540-77.Article PubMed
15. Fraser JF, Spooner AJ, Dunster KR, Anstey CM, Corley A. Nasal high flow oxygen therapy in patients with COPD reduces respiratory rate and tissue carbon dioxide while increasing tidal and end-expiratory lung volumes: a randomized crossover trial. Thorax 2016;71:759-61.Article PubMed PMC
16. Bräunlich J, Köhler M, Wirtz H. Nasal highflow improves ventilation in patients with COPD. Int J Chron Obstruct Pulmon Dis 2016;11:1077-85.Article PubMed PMC
17. Chatila W, Nugent T, Vance G, Gaughan J, Criner GJ. The effects of high-flow vs low-flow oxygen on exercise in advanced obstructive airways disease. Chest 2004;126:1108-15.Article PubMed
18. Pilcher J, Eastlake L, Richards M, Power S, Cripps T, Bibby S, et al. Physiological effects of titrated oxygen via nasal highflow cannulae in COPD exacerbations: a randomized controlled cross-over trial. Respirology 2017;22:1149-55.Article PubMed
19. British Thoracic Society Standards of Care Committee. Noninvasive ventilation in acute respiratory failure. Thorax 2002;57:192-211.Article PubMed PMC
20. Rawat D, Sharma S. Hypercapnea. Treasure Island: StatPearls Publishing. 2019.
21. Jubran A. Rapid shallow breathing: causes and consequences. In: Mancebo J, Net A, Brochard L, editors. Mechanical ventilation and weaning. Berlin, Heidelberg, Springer Berlin-Heidelberg; 2002. p. 161-8.
22. Miro AM, Shivaram U, Hertig I. Continuous positive airway pressure in COPD patients in acute hypercapnic respiratory failure. Chest 1993;103:266-8.Article PubMed
23. Jaoude P, Kufel T, El-Solh AA. Survival benefit of CPAP favors hypercapnic patients with the overlap syndrome. Lung 2014;192:251-8.Article PubMed PDF
24. Mauri T, Eronia N, Turrini C, Grasselli G, Bellani G, Pesenti A. High flow nasal cannula improves lung aeration and enhances CO₂ removal in hypoxemic critically ill patients. Intensive Care Med Exp 2015;3:A176. Article PMC
25. Austin MA, Wills KE, Blizzard L, Walters EH, Wood-Baker R. Effect of high flow oxygen on mortality in chronic obstructive pulmonary disease patients in prehospital setting: randomised controlled trial. BMJ 2010;341:c5462. Article PubMed PMC
26. Chang GY, Cox CA, Shaffer TH. Nasal cannula, CPAP, and highflow nasal cannula: effect of flow on temperature, humidity, pressure, and resistance. Biomed Instrum Technol 2011;45:69-74.Article PubMed
27. Jeffrey AA, Warren PM, Flenley DC. Acute hypercapnic respiratory failure in patients with chronic obstructive lung disease: risk factors and use of guidelines for management. Thorax 1992;47:34-40.Article PubMed PMC
28. Lee CC, Mankodi D, Shaharyar S, Ravindranathan S, Danckers M, Herscovici P, et al. High flow nasal cannula versus conventional oxygen therapy and non-invasive ventilation in adults with acute hypoxemic respiratory failure: a systematic review. Respir Med 2016;121:100-8.Article PubMed
29. Coudroy R, Jamet A, Petua P, Robert R, Frat JP, Thille AW. Highflow nasal cannula oxygen therapy versus noninvasive ventilation in immunocompromised patients with acute respiratory failure: an observational cohort study. Ann Intensive Care 2016;6:45. Article PubMed PMC PDF

Figure & Data

References

Citations

Citations to this article as recorded by

The Impact of High-Flow Nasal Cannula Therapy on Diaphragmatic Function Assessed by Ultrasound: A Pilot Clinical Study
Miriam Gotti, Michele Umbrello, Giovanni Sabbatini, Elena Alessandra Mantovani, Lorenzo Foggetti, Alessandro Menozzi, Andrea Galimberti, Angelo Pezzi, Paolo Formenti
Critical Care Medicine.2026; 54(3): 435. CrossRef
Airway Secretion Volume and Physiological Effects of High-Flow Nasal Cannula in Acute Respiratory Failure Because of Bronchiectasis
Nicolás Colaianni-Alfonso, Guillermo Montiel, Catalina Siroti, Mauro Castro-Sayat, Luigi Vetrugno, Claudia Crimi
Respiratory Care.2026;[Epub] CrossRef
Gas composition and pressure in the hypopharynx during high-flow oxygen therapy through a nasal cannula in healthy volunteers with different breathing patterns
Andrey I. Yaroshetskiy, Anna P. Krasnoshchekova, Fedor D. Tkachenko, Alina V. Rubashchenko, Daniil D. Zubarev, Vasiliy D. Konanykhin, Maxim I. Savelenok, Maxim M. Nosenko, Zamira M. Merzhoeva, Sergey N. Avdeev
BMC Anesthesiology.2025;[Epub] CrossRef
Physical and Physiological Mechanisms of Emergent Hydrodynamic Pressure in High-Flow Nasal Cannula Therapy
Jose Luis Estela-Zape
Advances in Respiratory Medicine.2025; 94(1): 1. CrossRef
Efficacy and safety of high-flow nasal cannula therapy in elderly patients with acute respiratory failure
J.M. Carratalá, S. Diaz-Lobato, B. Brouzet, P. Más-Serrano, J.L.S. Rocamora, A.G. Castro, A.G. Varela, S. Mayoralas-Alises
Pulmonology.2024; 30(5): 437. CrossRef
Comparison of preoxygenation with a high-flow nasal cannula and a simple face mask before intubation in patients with head and neck cancer
Jun-Young Jo, Jungpil Yoon, Heeyoon Jang, Wook-Jong Kim, Seungwoo Ku, Seong-Soo Choi
Acute and Critical Care.2024; 39(1): 61. CrossRef
Delivery of Aerosolized Bronchodilators by High-Flow Nasal Cannula During COPD Exacerbation
Nicolás Colaianni-Alfonso, Ronan MacLoughlin, Ariel Espada, Yasmine Saa, Mariano Techera, Ada Toledo, Guillermo Montiel, Mauro Castro-Sayat
Respiratory Care.2023; 68(6): 721. CrossRef
Successful noninvasive ventilation in a severely acidotic and hypercapnic comatose COVID-19 patient with multiple comorbidities: a case report
Joseph Abraham Poonuraparampil, Habib Md Reazaul Karim, Manu P Kesavankutty, Porika Prashanth Nayak
Acute and Critical Care.2022; 37(1): 120. CrossRef
Comparison of Conventional Oxygen Therapy With High-Flow Nasal Oxygenation in the Management of Hypercapnic Respiratory Failure
Jitendra Pratap Singh, Deepak Malviya, Samiksha Parashar, Soumya Sankar Nath, Archana Gautam, Neha Shrivastava
Cureus.2022;[Epub] CrossRef
Current Considerations in Emergency Airway Management
Andrew Pirotte, Vivek Panchananam, Matthew Finley, Austin Petz, Tom Herrmann
Current Emergency and Hospital Medicine Reports.2022; 10(4): 73. CrossRef
S/F and ROX indices in predicting failure of high‐flow nasal cannula in children
Ji Hye Kim, Dong In Suh, June Dong Park
Pediatrics International.2022;[Epub] CrossRef
Nasal High‐flow Oxygen Versus Conventional Oxygen Therapy for Acute Severe Asthma Patients: A Pilot Randomized Controlled Trial
Onlak Ruangsomboon, Chok Limsuwat, Nattakarn Praphruetkit, Apichaya Monsomboon, Tipa Chakorn, Brian C. Hiestand
Academic Emergency Medicine.2021; 28(5): 530. CrossRef
Flow Field Analysis of Adult High‐Flow Nasal Cannula Oxygen Therapy
Jingen Xia, Jiaqi Chang, Jixiang Liang, Yixuan Wang, Na Wang, Bo Xiao
Complexity.2021;[Epub] CrossRef
Treatment of Severe Acute on Chronic Liver Failure
Aarshi Vipani, Christina C. Lindenmeyer, Vinay Sundaram
Journal of Clinical Gastroenterology.2021; 55(8): 667. CrossRef
Efficacy of High-Flow Nasal Cannula Oxygen Therapy in Patients with Mild Hypercapnia
Lingling Su, Qinyu Zhao, Taotao Liu, Yujun Xu, Weichun Li, Aiping Zhang
Lung.2021; 199(5): 447. CrossRef
High-Flow Nasal Cannula Oxygen Therapy Can Be Effective for Patients in Acute Hypoxemic Respiratory Failure with Hypercapnia: a Retrospective, Propensity Score-Matched Cohort Study
SooHyun Bae, Minkyu Han, Changyoung Kim, Hyeji Lee, Jong-Joon Ahn, Jin Hyoung Kim, Byung Ju Kang
Journal of Korean Medical Science.2020;[Epub] CrossRef
High-flow nasal cannula oxygen therapy as an emerging option for respiratory failure: the present and the future
Lucia Spicuzza, Matteo Schisano
Therapeutic Advances in Chronic Disease.2020;[Epub] CrossRef
Impact of High-Flow Nasal Cannula on Arterial Blood Gas Parameters in the Emergency Department
Emre Şancı, Feride Ercan Coşkun, Basak Bayram
Cureus.2020;[Epub] CrossRef

PubReader
ePub Link

Cite

CITE: export Copy Format; Close

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:

RIS — For EndNote, ProCite, RefWorks, and most other reference management software
BibTeX — For JabRef, BibDesk, and other BibTeX-specific software

Include:

Citation for the content below
Citation and abstract for the content below

Reduction of PaCO₂ by high-flow nasal cannula in acute hypercapnic respiratory failure patients receiving conventional oxygen therapy

Acute Crit Care. 2019;34(3):202-211. Published online August 31, 2019

DOI: https://doi.org/10.4266/acc.2019.00563

XML Download

Figure

Reduction of PaCO₂ by high-flow nasal cannula in acute hypercapnic respiratory failure patients receiving conventional oxygen therapy

Figure 1. Flowchart showing the classification and propensity score matching of acute respiratory failure patients. HFNC: high-flow nasal cannula.

Figure 2. Sequential measurements of arterial partial pressure of carbon dioxide (PaCO2, A), pH (B), and arterial partial pressure of oxygen (PaO2, C) during the use of a high-flow nasal cannula.

Figure 3. Association between carbon dioxide (CO2) washout during the first 12 hours and initial arterial partial pressure of carbon dioxide (PaCO2) level.

Figure 4. Sequential measurements of respiratory rate (A) and heart rate (B) during the use of a high-flow nasal cannula.

Figure 5. Sequential measurements of fraction of inspired oxygen (FiO2, A) and oxygen (O2) flow rate (B) during the use of a high-flow nasal cannula.

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Reduction of PaCO₂ by high-flow nasal cannula in acute hypercapnic respiratory failure patients receiving conventional oxygen therapy

Variable	Hypercapnia group (n=18)	Nonhypercapnia group (n=177)	P-value
Age (yr)	70.5±12.2	66.0±13.1	0.166
Male sex	16 (88.9)	116 (65.6)	0.044
Body mass index (kg/m²)	20.9±2.7	21.4±3.7	0.601
Glasgow coma scale	14.5±1.2	14.9±0.4	0.243
Do not resuscitate	11 (61.1)	95 (53.7)	0.546
Do not intubate	7 (38.9)	59 (33.3)	0.635
Department
Medical intensive care unit	18 (100)	166 (93.8)	0.276
Previous history of ICU admission	6 (33.3)		-
Underlying disease
Cardiovascular disease	8 (44.4)	34 (19.2)	0.013
Cardiomyopathy	6 (33.3)	46 (26.0)	0.502
Diabetes mellitus	5 (27.8)	49 (27.7)	0.993
Chronic respiratory disease	8 (44.4)	46 (26.0)	0.095
Malignancy	9 (50.0)	107 (60.5)	0.389
Immune deficiency	6 (33.3)	109 (61.6)	0.020
Liver cirrhosis	4 (22.2)	17 (9.6)	0.100
Chronic kidney disease	5 (27.8)	27 (15.3)	0.172
Blood test
Total white blood cell count (/μl)	16,000±27,034	11,682±8,323	0.509
Hematocrit (%)	32.5±7.0	31.4±5.8	0.433
Creatinine (mg/dl)	2.2±2.1	1.4±1.3	0.161
PH	7.31±0.09	7.43±0.07	<0.001
PaO₂ (mm Hg)	64.5±21.4	73.0±25.2	0.168
PaCO₂ (mm Hg)	61.5±15.1	34.6±5.9	<0.001

Variable	Hypercapnia group (n=18)	Nonhypercapnia group (n=177)	P-value
Cause of respiratory failure^a
Pneumonia	11 (61.1)	121 (68.4)	0.531
Disease progression^b	3 (16.7)	21 (11.9)	0.555
Pulmonary edema	6 (33.3)	31 (17.5)	0.103
Acute exacerbation of COPD	3 (16.7)	10 (5.6)	0.074
Post-extubation respiratory failure	2 (11.1)	16 (9.0)	0.772
Sepsis	1 (5.6)	13 (7.3)	0.779
Pulmonary embolism	0	6 (3.4)	0.428
Other causes	1 (5.6)	8 (4.5)	0.842
Initial vital sign
Mean blood pressure (mm Hg)	91±15	92±15.0	0.537
Heart rate (/min)	101±23	103±22	0.736
Respiratory rate (/min)	29±7	27±7	0.434
Body temperature (°C)	37.4±0.7	37.4±0.9	0.931
Oxygen saturation (%)	90±6	90±6	0.609
Use of inotropics
Dobutamine	0	3 (1.7)	0.567
Dopamine	0	11 (6.2)	0.276
Norepinephrine	2 (11.1)	14 (7.9)	0.699
Initial setting of high flow oxygen therapy
O₂ flow rate (L/min)	43±10	42±9	0.555
FiO₂	0.58±0.18	0.66±0.16	0.037
APACHE II score	17.8±7.1	17.6±6.3	0.886
SOFA score	6.2±3.1	6.5±3.0	0.662
PF ratio	133±92	118±54	0.508

Variable	Hypercapnia group (n=18)	Nonhypercapnia group (n=18)	P-value
Age (yr)	70.5±12.2	72.2±9.3	0.648
Male sex	16 (88.9)	17 (94.4)	0.546
Body mass index (kg/m²)	20.9±2.7	20.8±2.5	0.879
Glasgow coma scale	14.5±1.2	14.8±0.4	0.378
Do not resuscitate	11 (61.1)	10 (55.6)	0.735
Do not intubate	7 (38.9)	6 (33.3)	0.729
Department
Medical ICU	18 (100)	18 (100)	-
Previous history of ICU admission	6 (33.3)	6 (33.3)	1.000
Underlying disease
Cardiovascular disease	8 (44.4)	11 (61.1)	0.317
Cardiomyopathy	6 (33.3)	8 (44.4)	0.494
Diabetes mellitus	5 (27.8)	5 (27.8)	1.000
Chronic respiratory disease	8 (44.4)	11 (61.1)	0.317
Malignancy	9 (50.0)	6 (33.3)	0.310
Immune deficiency	6 (33.3)	4 (22.2)	0.457
Liver cirrhosis	4 (22.2)	3 (16.7)	0.674
Chronic kidney disease	5 (27.8)	6 (33.3)	0.717
Blood test
Total white blood cell count (/μl)	16,000±27,034	16,386±11,984	0.956
Hematocrit (%)	32.5±7.0	33.3±5.8	0.721
Creatinine (mg/dl)	2.2±2.1	2.1±1.5	0.878
pH	7.31±0.09	7.42±0.07	<0.001
PaO₂ (mm Hg)	64.5±21.4	69.6±28.1	0.542
PaCO₂ (mm Hg)	61.5±15.1	37.1±6.1	<0.001

Variable	Hypercapnia group (n=18)	Nonhypercapnia group (n=18)	P-value
Cause of respiratory failure^a
Pneumonia	11 (61.1)	12 (66.7)	0.729
Disease progression^b	3 (16.7)	2 (11.1)	0.630
Pulmonary edema	6 (33.3)	7 (38.9)	0.729
Acute exacerbation of COPD	3 (16.7)	5 (27.8)	0.423
Post-extubation respiratory failure	2 (11.1)	2 (11.1)	1.000
Sepsis	1 (5.6)	1 (5.6)	1.000
Pulmonary embolism	0	0	-
Other causes	1 (5.6)	2 (11.1)	0.546
Initial vital sign
Mean blood pressure (mm Hg)	91±15	91±13	0.914
Heart rate (/min)	101±23	99±15	0.786
Respiratory rate (/min)	29±7	30±6	0.708
Body temperature (°C)	37.4±0.7	37.1±0.7	0.169
Oxygen saturation (%)	90±6	90±6	0.775
Use of inotropics
Dobutamine	0	1 (5.6)	1.000
Dopamine	0	2 (11.1)	0.486
Norepinephrine	2 (11.1)	1 (5.6)	1.000
Initial setting of high-flow O₂ therapy
O₂ flow rate (L/min)	43±10	45±8	0.648
FiO₂	0.58±0.18	0.69±0.16	0.052
APACHE II score	17.8±7.1	17.7±4.7	0.956
SOFA score	6.2±3.1	5.8±2.3	0.718
PF ratio	133±92	103±39	0.221

Variable	Hypercapnia group (n=18)	Nonhypercapnia group (n=18)	P-value
All-cause mortality	10 (55.6)	11 (61.1)	0.735
Cause of death			0.867
Respiratory failure	8 (80.0)	8 (72.7)
Septic shock	1 (10.0)	2 (18.2)
Cardiac arrest	1 (10.0)	1 (9.1)
Others
Survival time during the 28 days after initiation of HFNC (day)	16.9±9.7	17.2±5.4	0.522
Day without HFNC in 7 days	1.9±1.5	2.2±1.8	0.687
Day without HFNC in 14 days	8.8±1.8	8.1±3.7	0.462

Table 1. Baseline characteristics in the total study population

Values are presented as mean±standard deviation or number (%).

ICU: intensive care unit; PaO₂: arterial partial pressure of oxygen; PaCO₂: arterial partial pressure of carbon dioxide.

Table 2. Assessment of the clinical conditions in the total population

Values are presented as number (%) or mean±standard deviation.

One or more diseases were attributed to acute respiratory failure of each patient;

Progression of metastatic malignancy and chronic lung diseases such as interstitial lung disease and tuberculosis-destroyed lung are included.

Table 3. Baseline characteristics in the propensity score-matched population

Values are presented as mean±standard deviation or number (%).

ICU: intensive care unit; PaO₂: arterial partial pressure of oxygen; PaCO₂: arterial partial pressure of carbon dioxide.

Table 4. Assessment of clinical conditions in the propensity score–matched population

Values are presented as number (%) or mean±standard deviation.

One or more diseases were attributed to acute respiratory failure of each patient;

Progression of metastatic malignancy and chronic lung diseases such as interstitial lung disease and tuberculosis-destroyed lung are included.